[go: up one dir, main page]

ES2085983T3 - Antagonistas de anticuerpos de la interleuquina-4 humana. - Google Patents

Antagonistas de anticuerpos de la interleuquina-4 humana.

Info

Publication number
ES2085983T3
ES2085983T3 ES91902038T ES91902038T ES2085983T3 ES 2085983 T3 ES2085983 T3 ES 2085983T3 ES 91902038 T ES91902038 T ES 91902038T ES 91902038 T ES91902038 T ES 91902038T ES 2085983 T3 ES2085983 T3 ES 2085983T3
Authority
ES
Spain
Prior art keywords
antibodies
antagonists
link
cell receptors
antibody antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902038T
Other languages
English (en)
Inventor
Lata Ramanathan
Gail F Seelig
Paul P Trotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2085983T3 publication Critical patent/ES2085983T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ANTAGONISTAS DE ANTICUERPOS DE LA INTERLEUKINA-4 HUMANA ESTA INVENCION PRESENTA DOS TIPOS DE ANTAGONISTAS DE ANTICUERPOS DEL ENLACE DE LA IL-4 HUMANA A RECEPTORES CELULARES. ALGUNOS DE LOS ANTAGONISTAS SE ENLAZAN A REGIONES ESPECIFICAS DE LA IL-4 QUE SE PIENSA ESTAN RELACIONADOS CON LAS INTERACCIONES ENTRE LA IL-4 Y SUS RECEPTORES. DEBIDO A ESTE ENLACE ESPECIFICO MEDIANTE LOS ANTICUERPOS A LA IL-4, EL ENLACE DE LA IL-4 A LOS RECEPTORES SE INHIBE SUSTANCIALMENTE. LOS OTROS ANTAGONISTAS DE ANTICUERPOS DE LA INVENCION SON ANTICUERPOS ANTI-IDIOTIPICOS QUE, AL NO TENER UNA ACTIVIDAD IL-4, PARECEN IMITAR A LA IL-4 Y COMPETIR DIRECTAMENTE CON ELLA PARA UNIRSE A LOS RECEPTORES CELULARES. TAMBIEN SE PRESENTAN LOS POLIPEPTIDOS UTILIZADOS PARA HACER LOS ANTAGONISTAS DE ANTICUERPOS, JUNTO CON LOS METODOS PARA UTILIZAR LOS ANTAGONISTAS PARA INHIBIR EL ENLACE DE LA IL-4 A SUS RECEPTORES CELULARES.
ES91902038T 1989-12-20 1990-12-18 Antagonistas de anticuerpos de la interleuquina-4 humana. Expired - Lifetime ES2085983T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357089A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ES2085983T3 true ES2085983T3 (es) 1996-06-16

Family

ID=23801108

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902038T Expired - Lifetime ES2085983T3 (es) 1989-12-20 1990-12-18 Antagonistas de anticuerpos de la interleuquina-4 humana.

Country Status (26)

Country Link
US (1) US6358509B1 (es)
EP (1) EP0506826B1 (es)
JP (1) JPH0730116B2 (es)
KR (1) KR960016862B1 (es)
AT (1) ATE136906T1 (es)
AU (1) AU639754B2 (es)
CA (1) CA2071908C (es)
CZ (1) CZ283050B6 (es)
DE (1) DE69026627T2 (es)
DK (1) DK0506826T3 (es)
ES (1) ES2085983T3 (es)
FI (1) FI104180B1 (es)
GR (1) GR3020325T3 (es)
HU (1) HU215245B (es)
IE (1) IE74708B1 (es)
IL (1) IL96714A0 (es)
MX (1) MX9203401A (es)
MY (1) MY106507A (es)
NO (1) NO922457L (es)
NZ (1) NZ236511A (es)
OA (1) OA09704A (es)
PT (1) PT96230B (es)
SK (1) SK279933B6 (es)
TW (1) TW221675B (es)
WO (1) WO1991009059A1 (es)
ZA (1) ZA9010190B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
KR100398819B1 (ko) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH09502708A (ja) * 1993-09-07 1997-03-18 スミスクライン・ビーチャム・コーポレイション Ｉｌ４により伝達される疾患の治療に有用な組み換え型ｉｌ４抗体
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
EP1142961B1 (en) * 2000-04-06 2008-08-06 FUJIFILM Corporation Dye complex and optical information recording medium
EP2990420B1 (en) * 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
FR2838444B1 (fr) * 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
AU2003251633A1 (en) * 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
PL1711528T3 (pl) 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
RU2382049C2 (ru) * 2004-08-03 2010-02-20 Новартис Аг ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ-4 (hIL-4)
AR050044A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
ES2620437T3 (es) * 2008-11-17 2017-06-28 Københavns Universitet Péptidos derivados de IL-4 para la modulación de la respuesta inflamatoria crónica y el tratamiento de enfermedades autoinmunes
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP6161540B2 (ja) 2011-02-04 2017-07-12 ジェネンテック， インコーポレイテッド Ｆｃ変異体及びそれらの生産方法
BR112015024553A2 (pt) * 2013-04-05 2017-10-24 Genentech Inc anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
ES2955736T3 (es) 2014-05-06 2023-12-05 Hoffmann La Roche Producción de proteínas heteromultiméricas usando células de mamífero
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
ZA872781B (en) 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
FI903827A0 (fi) * 1988-02-02 1990-08-01 Schering Biotech Corp Foerfarande foer reducering av immunoglobulin e-responser.

Also Published As

Publication number Publication date
CA2071908C (en) 2002-04-30
IE904589A1 (en) 1991-07-03
EP0506826A1 (en) 1992-10-07
SK635290A3 (en) 1999-06-11
JPH0730116B2 (ja) 1995-04-05
CZ283050B6 (cs) 1997-12-17
TW221675B (es) 1994-03-11
FI922847A0 (fi) 1992-06-18
DE69026627T2 (de) 1996-08-22
HU9202073D0 (en) 1992-09-28
IL96714A0 (en) 1991-09-16
JPH04506359A (ja) 1992-11-05
PT96230B (pt) 1998-06-30
PT96230A (pt) 1991-10-15
MX9203401A (es) 1992-07-01
CZ635290A3 (en) 1997-08-13
FI104180B (fi) 1999-11-30
NZ236511A (en) 1993-02-25
IE74708B1 (en) 1997-07-30
GR3020325T3 (en) 1996-09-30
NO922457D0 (no) 1992-06-19
HU215245B (hu) 1998-11-30
DE69026627D1 (de) 1996-05-23
DK0506826T3 (da) 1996-05-13
AU639754B2 (en) 1993-08-05
OA09704A (en) 1993-08-30
CA2071908A1 (en) 1991-06-21
US6358509B1 (en) 2002-03-19
HUT64568A (en) 1994-01-28
FI922847L (fi) 1992-06-18
KR920703642A (ko) 1992-12-18
KR960016862B1 (ko) 1996-12-23
MY106507A (en) 1995-06-30
AU7176291A (en) 1991-07-18
EP0506826B1 (en) 1996-04-17
ATE136906T1 (de) 1996-05-15
NO922457L (no) 1992-06-19
SK279933B6 (sk) 1999-06-11
ZA9010190B (en) 1991-08-28
FI104180B1 (fi) 1999-11-30
WO1991009059A1 (en) 1991-06-27

Similar Documents

Publication Publication Date Title
ES2085983T3 (es) Antagonistas de anticuerpos de la interleuquina-4 humana.
DE3765782D1 (de) Pyrazolin mit insektizidischer aktivitaet.
ES2173873T3 (es) Utilizacion de anticuerpos anti-vegf para el tratammiento del cancer.
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
ES2149772T3 (es) Receptores humanos pf4a y su utilizacion.
GR1000023B (el) Καρβαμικος φαινυλεστηρ.
ES2128362T3 (es) Fragmentos de proteinas de prion.
SE8803084L (sv) Dosform innefattande en snabb avgivning av ett medel foeljt av laangsam avgivning av ett medel
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
ES2053719T3 (es) Dimetilvermectinas no naturales y procedimiento para su preparacion.
ES2043607T3 (es) Agentes fibrinoliticos modificados.
FR2350106A1 (fr) Lame de verification de sterilite biologique echelonnee
ES2118058T3 (es) Factor de crecimiento de las celulas t.
ES421146A1 (es) Conjunto de acoplamiento para tensar estructuras de hormi- gon postensado de varios tramos.
ES2147761T3 (es) Metodo para la deteccion de alteraciones de los huesos y otros tejidos conectivos en los seres humanos y los animales.
ES2091292T3 (es) Metodo para la determinacion inmunologica del polipeptido carboxiterminal de procolageno de tipo i.
ATE103147T1 (de) Stuhlkonstruktion zum aufbau von stuhlreihen.
MX9300602A (es) Analogos de fenilalanina de bombesina.
ES2131218T3 (es) Utilizacion de anticuerpos anti-idiotipicos para evitar el rechazo hiperagudo de los injertos entre dos especies diferentes.
ES2052913T3 (es) Ensayo inmunoquimico en cuanto al factor estimulante de colonias de granulocitos-macrofagos.
ES8303449A1 (es) "procedimiento para la preparacion de compuestos derivados de alfa-d-galactopiranosido".
ES2044893T3 (es) Un anticuerpo monoclonal especifico para un inhibidor de la coagulacion.
ES2082468T3 (es) Arilalquil esteres del acido 4,5-dihidroxi-9,10-dihidro-9,10-dioxo-2-antracenocarboxilico con actividad terapeutica.
ES2092170T3 (es) Antagonistas de receptores de fibrinogeno marcados con tritio, su utilizacion y procedimiento para su preparacion.
ES456306A1 (es) Procedimiento para la identificacion selectiva del organismo"e. coli".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506826

Country of ref document: ES